Receptos, Inc. (RCPT) in Focus: Stock Jumps 5.2% - Tale of the Tape
Receptos, Inc. ( RCPT ) was a big mover last session, as the company saw its shares rise over 5% on the day. The upside came after the company announced that it has completed the enrolment of patients in the RADIANCE Phase III trial on ozanimod on patients suffering from relapsing multiple sclerosis. The news led to far more shares changing hands than in a normal session resulting in solid volume. This continues the recent uptrend for the company as the stock is now up 36.47% in the past one-month time frame.
None of the estimates for this medical drugs stock were revised over the past seven days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Receptos currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.
A better-ranked stock in the same industry is ArQule Inc. ( ARQL ), carrying a Zacks Rank #1 (Strong Buy).